Reflections/NNS
on/IN
the/DT
US/NN
FDA/NN
's/POS
Warning/NN
on/IN
Direct-to-Consumer/NN
Genetic/JJ
Testing/JJ
./.
====================
In/IN
November/NN
2013/CD
,/,
the/DT
US/NN
Food/JJ
and/CC
Drug/NN
Administration/NN
(/(
FDA/NN
)/)
sent/JJ
a/DT
warning/VBG
letter/RBR
to/TO
23andMe/JJ
,/,
Inc./NNP
and/CC
ordered/VBN
the/DT
company/JJ
to/TO
discontinue/JJ
marketing/VBG
of/IN
the/DT
23andMe/JJ
Personal/JJ
Genome/NN
Service/NN
(/(
PGS/NN
)/)
until/IN
it/PRP
receives/VBZ
FDA/NN
marketing/VBG
authorization/NN
for/IN
the/DT
device/JJ
./.
====================
The/DT
FDA/NN
considers/VBZ
the/DT
PGS/NN
as/IN
an/DT
unclassified/JJ
medical/JJ
device/RB
,/,
which/WDT
requires/VBZ
premarket/NN
approval/JJ
or/CC
de/FW
novo/FW
classification/NN
./.
====================
Opponents/NNS
of/IN
the/DT
FDA/NN
's/POS
action/NN
expressed/VBD
their/PRP$
concerns/NNS
,/,
saying/VBG
that/DT
the/DT
FDA/NN
is/VBZ
overcautious/JJ
and/CC
paternalistic/JJ
,/,
which/WDT
violates/VBZ
consumers/NNS
'/``
rights/NNS
and/CC
might/MD
stifle/JJ
the/DT
consumer/NN
genomics/NNS
field/NN
itself/PRP
,/,
and/CC
insisted/JJ
that/DT
the/DT
agency/NN
should/MD
not/RB
restrict/VB
direct-to-consumer/JJ
(/(
DTC/NN
)/)
genomic/JJ
testing/VBG
without/IN
empirical/JJ
evidence/NN
of/IN
harm/NN
./.
====================
Proponents/NNS
support/VBP
the/DT
agency/NN
's/POS
action/NN
as/IN
protection/NN
of/IN
consumers/NNS
from/IN
potentially/RB
invalid/JJ
and/CC
almost/RB
useless/NN
information/NN
./.
====================
This/DT
action/NN
was/VBD
also/RB
significant/JJ
,/,
since/IN
it/PRP
reflected/VBD
the/DT
FDA/NN
's/POS
attitude/NN
towards/IN
medical/JJ
application/NN
of/IN
next-generation/NN
sequencing/NN
techniques/NNS
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
followed/VBD
up/IN
on/IN
the/DT
FDA-23andMe/NN
incident/JJ
and/CC
evaluated/VBD
the/DT
problems/NNS
and/CC
prospects/NNS
for/IN
DTC/NN
genetic/JJ
testing/NN
./.
====================
On/IN
November/NN
22/CD
,/,
2013/CD
,/,
the/DT
US/NN
Food/JJ
and/CC
Drug/NN
Administration/NN
(/(
FDA/NN
)/)
sent/JJ
a/DT
warning/VBG
letter/RBR
to/TO
Ann/JJ
Wojcicki/NNP
,/,
co-founder/RB
and/CC
CEO/NN
of/IN
23andMe/JJ
,/,
Inc./NNP
and/CC
ordered/VBN
the/DT
company/JJ
to/TO
``/DT
immediately/RB
discontinue/JJ
marketing/VBG
of/IN
the/DT
23andMe/JJ
Saliva/NNP
Collection/NN
Kit/NN
and/CC
Personal/JJ
Genome/NNP
Service/NN
(/(
PGS/NN
)/)
until/IN
such/JJ
time/NN
as/IN
it/PRP
receives/VBZ
FDA/NN
marketing/VBG
authorization/NN
for/IN
the/DT
device/JJ
''/NNP
[/(
1/CD
]/)
./.
====================
Since/IN
23andMe/JJ
is/VBZ
one/CD
of/IN
the/DT
largest/JJS
direct-to-consumer/JJ
(/(
DTC/NN
)/)
genetic/JJ
testing/NN
companies/NNS
leading/VBG
the/DT
field/NN
,/,
the/DT
FDA/NN
's/POS
action/NN
could/MD
have/VB
big/NN
implications/NNS
for/IN
the/DT
present/JJ
and/CC
future/JJ
./.
====================
This/DT
FDA/NN
letter/NN
was/VBD
even/RB
called/VBN
a/DT
``/JJ
bombshell/NN
''/CD
in/IN
one/CD
Nature/NN
Editorial/JJ
[/(
2/CD
]/)
./.
====================
Various/JJ
responses/NNS
and/CC
speculation/NN
have/VBP
followed/VBN
./.
====================
Some/DT
people/JJ
support/VBP
the/DT
FDA/NN
's/POS
action/NN
as/IN
protection/NN
of/IN
consumers/NNS
from/IN
potentially/RB
invalid/JJ
information/NN
,/,
while/IN
others/NNS
insist/RB
that/DT
the/DT
FDA/NN
's/POS
action/NN
violates/VBZ
the/DT
rights/NNS
of/IN
individuals/NNS
to/TO
receive/JJ
information/NN
and/CC
of/IN
'commercial/JJ
speech/RB
'/``
and/CC
undermines/NNS
democratization/NN
of/IN
health/NN
care/JJ
and/CC
patient/NN
empowerment/JJ
[/(
3/CD
]/)
./.
====================
One/CD
of/IN
those/DT
responses/NNS
is/VBZ
noteworthy/RB
:/:
7/CD
months/NNS
after/IN
the/DT
FDA/NN
's/POS
action/NN
,/,
in/IN
June/JJ
2014/CD
,/,
Lee/NNP
and/CC
Lee/NNP
[/(
4/CD
]/)
of/IN
the/DT
Korea/NN
Health/RB
Industry/RB
Development/JJ
Institute/RB
(/(
KHIDI/NN
)/)
submitted/VBN
a/DT
report/JJ
to/TO
the/DT
Public-Private/JJ
Joint/JJ
Regulatory/JJ
Advancement/JJ
Initiative/JJ
(/(
PPJRAI/NN
)/)
,/,
titled/JJ
``/NNP
Market/NNP
Analysis/NN
and/CC
Strategies/NNS
for/IN
Regulatory/JJ
Reform/NN
in/IN
Medical/JJ
Industry/RB
,/,
''/NNP
which/WDT
expressed/VBD
a/DT
stance/RB
somehow/RB
different/JJ
from/IN
that/DT
of/IN
the/DT
US/NN
FDA/NN
./.
====================
To/TO
facilitate/VB
the/DT
discussion/NN
in/IN
our/PRP$
scientific/JJ
community/NN
,/,
we/PRP
examined/VBD
the/DT
development/NN
of/IN
the/DT
23andMe/JJ
event/NN
and/CC
reflected/VBD
on/IN
the/DT
future/JJ
of/IN
genetic-genome/JJ
testing/VBG
,/,
including/VBG
whole-genome/JJ
sequencing/NN
as/IN
a/DT
medical/JJ
device/RB
./.
====================
DTC/NN
genetic/JJ
testing/NN
,/,
also/RB
known/VBN
as/IN
at-home/DT
genetic/JJ
testing/NN
,/,
refers/VBZ
to/TO
genetic/JJ
tests/NNS
that/IN
are/VBP
sold/JJ
directly/RB
to/TO
consumers/NNS
via/IN
the/DT
internet/JJ
,/,
television/NN
,/,
or/CC
print/JJ
advertisement/JJ
without/IN
necessarily/RB
involving/VBG
health/NN
care/JJ
providers/NNS
./.
====================
Su/NNP
[/(
5/CD
]/)
grouped/VBD
the/DT
reasons/NNS
for/IN
using/VBG
DTC/NN
genetic/JJ
tests/NNS
into/IN
three/CD
categories/NNS
;/:
identity/NN
(/(
such/JJ
as/IN
ancestry/NN
,/,
paternity/NN
,/,
or/CC
ethnicity/NN
)/)
-seeking/JJ
;/:
disease/NN
risk-testing/VBG
to/TO
complement/VB
health/NN
care/JJ
;/:
and/CC
curiosity-driven/JJ
testing/VBG
./.
====================
DTC/NN
genetic/JJ
testing/NN
has/VBZ
its/PRP$
pros/NN
and/CC
cons/NNS
./.
====================
It/PRP
is/VBZ
more/RBR
accessible/JJ
and/CC
affordable/JJ
than/IN
traditional/JJ
genetic/JJ
tests/NNS
,/,
which/WDT
usually/RB
target/NN
one/CD
specific/JJ
gene/NN
at/IN
a/DT
time/NN
./.
====================
DTC/NN
testing/VBG
companies/NNS
and/CC
many/JJ
personalized/VBN
medicine/JJ
advocates/VBZ
argue/VBP
that/IN
knowing/VBG
the/DT
genetic/JJ
risks/NNS
for/IN
potential/JJ
diseases/NNS
will/MD
help/VB
people/JJ
to/TO
improve/VB
their/PRP$
health/NN
and/CC
wellness/RB
by/IN
changing/VBG
what/WP
they/PRP
can/MD
and/CC
managing/VBG
what/WP
they/PRP
can/MD
not/RB
,/,
as/IN
claimed/VBN
in/IN
23andMe/JJ
's/POS
TV/NN
commercial/JJ
[/(
6/CD
]/)
./.
====================
23andMe/DT
,/,
one/CD
of/IN
the/DT
largest/JJS
DTC/NN
genetic/JJ
testing/NN
companies/NNS
,/,
also/RB
made/VBD
the/DT
same/JJ
claims/NNS
and/CC
has/VBZ
offered/VBN
the/DT
PGS/NN
to/TO
>/JJR
475,000/CD
customers/NNS
since/IN
2007/CD
[/(
7/CD
]/)
./.
====================
23andMe/DT
's/POS
PGS/NN
genotypes/NNS
the/DT
DNA/NN
sample/NN
on/IN
their/PRP$
custom/JJ
single-nucleotide/JJ
polymorphism/NN
(/(
SNP/NN
)/)
chip/NN
and/CC
provides/VBZ
health/NN
reports/NNS
on/IN
254/CD
diseases/NNS
and/CC
traits/VBZ
,/,
including/VBG
carrier/NN
status/NN
and/CC
drug/NN
response/NN
,/,
which/WDT
,/,
the/DT
company/JJ
claims/NNS
,/,
enables/VBZ
customers/NNS
to/TO
personalize/VB
their/PRP$
health/NN
care/JJ
./.
====================
Additionally/RB
,/,
some/DT
proponents/NNS
suggest/VBP
,/,
as/IN
another/DT
argument/JJ
,/,
that/DT
DTC/NN
genetic/JJ
testing/NN
can/MD
contribute/VB
to/TO
the/DT
empowerment/JJ
of/IN
consumers/NNS
by/IN
increasing/VBG
knowledge/NN
and/CC
to/TO
subsequent/JJ
democratization/NN
of/IN
health/NN
care/JJ
[/(
5/CD
]/)
./.
====================
However/RB
,/,
many/JJ
geneticists/NNS
and/CC
physicians/NNS
have/VBP
rejected/VBN
the/DT
claims/NNS
./.
====================
They/PRP
believe/VBP
that/IN
since/IN
DTC/NN
genetic/JJ
testing/NN
is/VBZ
not/RB
reliable/JJ
enough/IN
to/TO
be/VB
used/VBN
clinically/RB
,/,
it/PRP
will/MD
just/RB
end/NN
up/IN
increasing/VBG
health/NN
care/JJ
costs/NNS
unnecessarily/RB
[/(
8/CD
]/)
./.
====================
Apart/RB
from/IN
its/PRP$
scientific/JJ
weaknesses/NNS
and/CC
insufficient/JJ
clinical/JJ
utility/NN
,/,
there/EX
are/VBP
other/JJ
concerns/NNS
raised/VBD
by/IN
critics/NNS
,/,
including/VBG
psychological/JJ
and/CC
financial/JJ
damage/NN
to/TO
consumers/NNS
,/,
especially/RB
by/IN
unreliable/JJ
test/NN
results/VBZ
,/,
health/NN
care/JJ
inequity/NN
,/,
and/CC
genetic/JJ
privacy/NN
./.
====================
Since/IN
we/PRP
believe/VBP
that/IN
scientific/JJ
validity/NN
is/VBZ
the/DT
foremost/JJ
foundation/NN
of/IN
DTC/NN
genetic/JJ
testing/NN
and/CC
should/MD
presuppose/VB
its/PRP$
clinical/JJ
usage/NN
,/,
we/PRP
will/MD
focus/VB
on/IN
it/PRP
in/IN
this/DT
review/NN
./.
====================
There/EX
are/VBP
quite/RB
a/DT
few/JJ
scientific/JJ
limitations/NNS
to/TO
genome-based/VBN
health/NN
risk/NN
estimation/NN
services/VBZ
in/IN
general/JJ
,/,
not/RB
just/RB
23andMe/JJ
's/POS
PGS/NN
,/,
but/CC
they/PRP
may/MD
not/RB
be/VB
apparent/JJ
,/,
even/RB
to/TO
medical/JJ
professionals/NNS
,/,
who/WP
do/VBP
not/RB
have/VB
enough/IN
knowledge/NN
in/IN
genetics/NNS
and/CC
genomics/NNS
,/,
as/IN
well/RB
as/IN
lay/RB
customers/NNS
./.
====================
First/RB
of/IN
all/DT
,/,
for/IN
monogenic/JJ
disorders/NNS
,/,
DTC/NN
genetic/JJ
testing/NN
panels/NNS
include/VBP
a/DT
small/JJ
fraction/NN
of/IN
known/VBN
disease-causing/VBG
mutations/NNS
or/CC
sometimes/RB
just/RB
include/VBP
mutations/NNS
present/JJ
only/RB
in/IN
specific/JJ
populations/NNS
./.
====================
This/DT
incompleteness/VBP
of/IN
testing/VBG
results/NNS
in/IN
misinterpretations/NNS
,/,
which/WDT
makes/VBZ
its/PRP$
clinical/JJ
value/NN
doubtful/JJ
./.
====================
Also/RB
,/,
for/IN
polygenicmultifactorial/JJ
disorders/NNS
and/CC
conditions/NNS
,/,
DTC/NN
testing/VBG
panels/NNS
include/VBP
only/RB
a/DT
small/JJ
percentage/NN
of/IN
the/DT
markers/NNS
among/IN
many/JJ
known/JJ
associated/VBN
markers/NNS
,/,
not/RB
to/TO
mention/NN
unknown/JJ
ones/NNS
,/,
which/WDT
also/RB
makes/VBZ
the/DT
risk/NN
prediction/NN
incomplete/JJ
and/CC
,/,
as/IN
a/DT
result/NN
,/,
inaccurate/JJ
./.
====================
We/PRP
also/RB
should/MD
not/RB
forget/VB
that/DT
gene-gene/NN
and/CC
gene-environment/JJ
interactions/NNS
are/VBP
not/RB
taken/VBN
into/IN
consideration/NN
for/IN
risk/NN
estimation/NN
at/IN
all/DT
./.
====================
In/IN
addition/NN
,/,
it/PRP
is/VBZ
hard/VBN
to/TO
say/VB
that/DT
their/PRP$
algorithms/NNS
for/IN
estimating/VBG
total/JJ
combined/JJ
risks/NNS
are/VBP
very/RB
well/RB
validated/VBN
./.
====================
In/IN
summary/NN
,/,
genome-based/VBN
DTC/NN
tests/NNS
are/VBP
incomplete/JJ
,/,
and/CC
the/DT
interpretation/NN
of/IN
their/PRP$
results/NNS
is/VBZ
hardly/RB
valid/NN
./.
====================
The/DT
biology/NN
is/VBZ
much/RB
more/RBR
complicated/VBN
than/IN
some/DT
health/NN
care/JJ
entrepreneurs/VBZ
believe/VBP
,/,
and/CC
genotypes/NNS
and/CC
sequences/NNS
are/VBP
not/RB
information/NN
but/CC
are/VBP
just/RB
basic/JJ
tools/NNS
to/TO
use/VB
for/IN
understanding/VBG
biology/NN
./.
====================
Even/RB
in/IN
the/DT
case/NN
of/IN
valid/JJ
associations/NNS
that/IN
have/VBP
been/VBN
replicated/VBN
by/IN
many/JJ
studies/NNS
,/,
the/DT
effect/NN
sizes/NNS
of/IN
most/JJS
SNPs/NNS
on/IN
specific/JJ
diseases/NNS
seem/VBP
to/TO
be/VB
small/JJ
to/TO
modest/VB
[/(
9/CD
]/)
./.
====================
Secondly/RB
,/,
even/RB
though/IN
their/PRP$
customers/NNS
are/VBP
provided/VBN
detailed/JJ
background/NN
information/NN
on/IN
the/DT
method/NN
used/VBN
for/IN
genotyping/VBG
and/CC
the/DT
statistical/JJ
interpretation/NN
,/,
which/WDT
supposedly/RB
helps/VBZ
their/PRP$
understanding/NN
,/,
there/EX
is/VBZ
still/RB
ample/JJ
possibility/NN
for/IN
misconceptions/NNS
./.
====================
Some/DT
professional/JJ
societies/NNS
have/VBP
issued/VBN
statements/NNS
on/IN
DTC/NN
genetic/JJ
testing/NN
./.
====================
The/DT
American/JJ
College/NN
of/IN
Medicine/NN
Genetics/NNS
said/JJ
,/,
in/IN
their/PRP$
2003/CD
statement/JJ
,/,
that/DT
due/JJ
to/TO
the/DT
complexities/NNS
of/IN
testing/VBG
and/CC
counseling/VBG
,/,
patients/NNS
'/``
use/NN
of/IN
DTC/NN
genetic/JJ
testing/NN
kits/NNS
may/MD
pose/VB
harms/VBZ
,/,
which/WDT
include/VBP
the/DT
following/VBG
:/:
test/DT
utilization/NN
for/IN
inappropriate/JJ
purposes/NNS
,/,
misinterpretation/NN
of/IN
test/NN
results/VBZ
,/,
and/CC
lack/VBP
of/IN
necessary/JJ
follow-up/JJ
[/(
10/CD
]/)
./.
====================
In/IN
2007/CD
,/,
the/DT
American/NN
Society/NN
of/IN
Human/JJ
Genetics/NNS
also/RB
expressed/VBD
their/PRP$
concerns/NNS
in/IN
a/DT
statement/JJ
on/IN
DTC/NN
genetic/JJ
testing/NN
,/,
saying/VBG
that/DT
consumers/VBZ
are/VBP
at/IN
risk/NN
of/IN
harm/NN
if/IN
the/DT
quality/NN
of/IN
tests/NNS
is/VBZ
not/RB
high/JJ
enough-i.e./FW
,/,
the/DT
analytical/JJ
or/CC
clinical/JJ
validity/NN
and/CC
clinical/JJ
utility/NN
of/IN
tests/NNS
are/VBP
not/RB
appropriate/JJ
[/(
11/CD
]/)
./.
====================
Analytical/JJ
validity/NN
shows/VBZ
how/WRB
accurately/RB
and/CC
reliably/RB
the/DT
test/NN
detects/VBZ
a/DT
specific/JJ
genetic/JJ
variant/NN
./.
====================
Clinical/JJ
validity/NN
shows/VBZ
how/WRB
well/RB
the/DT
genetic/JJ
variant/NN
is/VBZ
related/JJ
to/TO
the/DT
existence/NN
or/CC
risk/NN
of/IN
a/DT
specific/JJ
disease/NN
or/CC
condition/NN
./.
====================
Clinical/JJ
utility/NN
shows/VBZ
how/WRB
likely/JJ
the/DT
test/NN
can/MD
improve/VB
patient/NN
outcomes/NNS
[/(
12/CD
]/)
./.
====================
Consumers/NNS
are/VBP
also/RB
at/IN
risk/NN
of/IN
harm/NN
if/IN
claims/NNS
made/VBD
about/IN
tests/NNS
are/VBP
misleading/VBG
or/CC
simply/RB
false/VBP
and/CC
if/IN
information/NN
and/CC
counseling/VBG
are/VBP
not/RB
properly/RB
provided/VBD
to/TO
enable/VB
the/DT
consumer/NN
to/TO
make/VB
an/DT
informed/VBN
decision/NN
about/RB
whether/IN
to/TO
take/VB
the/DT
test/NN
or/CC
not/RB
and/CC
about/RB
what/WP
actions/NNS
to/TO
take/VB
after/IN
the/DT
genetic/JJ
test/NN
[/(
11/CD
]/)
./.
====================
Due/IN
to/TO
these/DT
criticisms/NNS
and/CC
repeated/VBN
interventions/NNS
from/IN
regulators/NNS
,/,
including/VBG
the/DT
US/NN
FDA/NN
,/,
especially/RB
in/IN
the/DT
United/JJ
States/NNS
,/,
the/DT
DTC/NN
market/NN
does/VBZ
not/RB
look/VB
very/RB
promising/JJ
at/IN
this/DT
moment/NN
./.
====================
Even/RB
one/CD
Nature/NN
Editorial/JJ
said/JJ
that/DT
DTC/NN
genetic/JJ
testing/NN
is/VBZ
not/RB
yet/RB
a/DT
viable/JJ
business/RB
model/NN
,/,
and/CC
most/JJS
firms/NNS
in/IN
the/DT
market/NN
have/VBP
stopped/VBN
providing/VBG
services/VBZ
involved/VBN
with/IN
personal/JJ
disease/NN
risk/NN
estimation/NN
or/CC
have/VBP
even/RB
totally/RB
shut/RB
down/RB
[/(
2/CD
]/)
./.
====================
On/IN
November/NN
22/CD
,/,
2013/CD
,/,
the/DT
US/NN
FDA/NN
sent/JJ
a/DT
warning/VBG
letter/RBR
to/TO
23andMe/JJ
,/,
Inc./NNP
and/CC
ordered/VBN
the/DT
company/JJ
to/TO
immediately/RB
cease/JJ
marketing/VBG
of/IN
their/PRP$
Saliva/NN
Collection/NN
Kit/NN
and/CC
PGS/NN
until/IN
it/PRP
received/VBD
proper/JJ
marketing/VBG
authorization/NN
for/IN
the/DT
device/JJ
[/(
1/CD
]/)
./.
====================
This/DT
letter/NN
was/VBD
sent/JJ
after/IN
the/DT
firm/JJ
failed/VBD
to/TO
provide/VB
additional/JJ
information/NN
on/IN
the/DT
analytical/JJ
and/CC
clinical/JJ
validity/NN
of/IN
the/DT
PGS/NN
the/DT
FDA/NN
requested/VBD
./.
====================
It/PRP
said/JJ
that/DT
although/IN
the/DT
FDA/NN
has/VBZ
been/VBN
diligently/RB
working/VBG
to/TO
help/VB
the/DT
company/JJ
comply/RB
with/IN
regulatory/JJ
requirements/NNS
since/IN
July/RB
2009/CD
,/,
it/PRP
stopped/VBD
communicating/VBG
with/IN
the/DT
FDA/NN
since/IN
May/NN
./.
====================
Apparently/RB
making/VBG
matters/NNS
worse/NN
,/,
the/DT
company/JJ
initiated/VBN
new/JJ
marketing/VBG
campaigns/NNS
,/,
including/VBG
TV/NN
commercials/NNS
./.
====================
This/DT
made/VBD
the/DT
FDA/NN
conclude/VBP
that/IN
the/DT
company/JJ
intends/VBZ
to/TO
expand/VB
the/DT
PGS/NN
's/POS
uses/VBZ
and/CC
consumer/NN
base/NN
without/IN
obtaining/VBG
marketing/VBG
authorization/NN
from/IN
the/DT
agency/NN
[/(
2/CD
]/)
./.
====================
The/DT
FDA/NN
clearly/RB
stated/VBN
that/DT
their/PRP$
PGS/NN
requires/VBZ
marketing/VBG
approval/JJ
,/,
because/IN
it/PRP
is/VBZ
intended/VBN
for/IN
use/NN
``/CD
in/IN
the/DT
diagnosis/NN
of/IN
disease/NN
or/CC
other/JJ
conditions/NNS
or/CC
in/IN
the/DT
cure/JJ
,/,
mitigation/NN
,/,
treatment/NN
,/,
or/CC
prevention/NN
of/IN
disease/NN
,/,
or/CC
is/VBZ
intended/VBN
to/TO
affect/VB
the/DT
structure/NN
or/CC
function/NN
of/IN
the/DT
body/NN
./.
''/CD
====================
In/IN
other/JJ
words/NNS
,/,
the/DT
FDA/NN
considers/VBZ
the/DT
PGS/NN
an/DT
unclassified/JJ
medical/JJ
device/RB
,/,
which/WDT
requires/VBZ
premarket/NN
approval/JJ
or/CC
de/FW
novo/FW
classification/NN
[/(
1/CD
]/)
./.
====================
After/IN
receiving/VBG
the/DT
letter/NN
,/,
on/IN
November/NN
26/CD
,/,
2014/CD
,/,
Wojcicki/NNP
acknowledged/VBD
in/IN
a/DT
blog/NN
post/RB
that/DT
they/PRP
were/VBD
behind/RB
schedule/NN
with/IN
their/PRP$
responses/NNS
to/TO
the/DT
FDA/NN
and/CC
that/IN
the/DT
agency/NN
needs/VBZ
to/TO
be/VB
convinced/VBN
of/IN
the/DT
quality/NN
of/IN
their/PRP$
PGS/NN
data/NNS
./.
====================
On/IN
December/NN
5/CD
,/,
2013/CD
,/,
the/DT
company/JJ
announced/JJ
that/DT
it/PRP
would/MD
suspend/VB
its/PRP$
health-related/JJ
genetic/JJ
tests/NNS
to/TO
comply/RB
with/IN
the/DT
US/NN
FDA/NN
's/POS
directive/JJ
during/IN
the/DT
regulatory/JJ
review/NN
process/NN
[/(
13/CD
]/)
./.
====================
Based/VBN
on/IN
the/DT
letter/NN
,/,
the/DT
FDA/NN
does/VBZ
not/RB
seem/VB
to/TO
think/VB
that/DT
the/DT
analytical/JJ
validity/NN
of/IN
23andMe/JJ
's/POS
SNP/NN
genotyping/VBG
is/VBZ
a/DT
problem/NN
per/IN
se/FW
as/IN
far/RB
as/IN
its/PRP$
results/NNS
are/VBP
correct/JJ
but/CC
feels/VBZ
that/DT
the/DT
clinical/JJ
validity/NN
of/IN
risk/NN
estimation/NN
has/VBZ
yet/RB
to/TO
be/VB
validated/VBN
,/,
which/WDT
may/MD
be/VB
practically/RB
impossible/JJ
./.
====================
After/IN
that/DT
,/,
23andMe/JJ
announced/JJ
that/DT
it/PRP
has/VBZ
been/VBN
working/VBG
with/IN
the/DT
FDA/NN
,/,
and/CC
the/DT
agency/NN
seemed/VBN
to/TO
consider/VB
the/DT
firm/JJ
's/POS
response/NN
to/TO
be/VB
adequate/JJ
[/(
14/CD
]/)
./.
====================
However/RB
,/,
the/DT
firm/JJ
is/VBZ
not/RB
able/JJ
to/TO
provide/VB
any/DT
timeline/JJ
for/IN
resuming/VBG
their/PRP$
PGS/NN
./.
====================
The/DT
US/NN
FDA/NN
's/POS
action/NN
evoked/VBN
mixed/JJ
reactions/NNS
./.
====================
Some/DT
expressed/VBN
their/PRP$
concerns/NNS
,/,
saying/VBG
that/DT
the/DT
FDA/NN
is/VBZ
overcautious/JJ
and/CC
paternalistic/JJ
and/CC
hinders/NNS
medical/JJ
advances/NNS
./.
====================
According/VBG
to/TO
Green/JJ
and/CC
Farahany/JJ
[/(
3/CD
]/)
,/,
the/DT
FDA/NN
's/POS
action/NN
violates/VBZ
the/DT
rights/NNS
of/IN
individuals/NNS
to/TO
receive/JJ
information/NN
and/CC
of/IN
'commercial/JJ
speech/JJ
'/``
and/CC
undermines/NNS
the/DT
democratization/NN
of/IN
health/NN
care/JJ
and/CC
patient/NN
empowerment/JJ
./.
====================
Also/RB
,/,
they/PRP
were/VBD
concerned/VBN
that/IN
this/DT
kind/NN
of/IN
overcautious/JJ
regulation/NN
might/MD
stifle/VB
the/DT
consumer/NN
genomics/NNS
field/NN
itself/PRP
and/CC
insisted/JJ
that/DT
the/DT
agency/NN
should/MD
not/RB
restrict/VB
DTC/NN
genomic/JJ
testing/NN
without/IN
empirical/JJ
evidence/NN
of/IN
harm/NN
./.
====================
However/RB
,/,
rather/RB
ironically/RB
,/,
they/PRP
ended/VBD
up/IN
emphasizing/VBG
the/DT
PGS/NN
's/POS
poor/JJ
clinical/JJ
utility/NN
by/IN
saying/VBG
that/DT
health-related/JJ
interpretations/NNS
of/IN
the/DT
PGS/NN
,/,
particularly/RB
about/RB
common/JJ
genetic/JJ
variants/NNS
,/,
relate/VBP
only/RB
indirectly/RB
to/TO
preventing/VBG
or/CC
diagnosing/VBG
disease/NN
[/(
4/CD
]/)
./.
====================
If/IN
their/PRP$
comment/JJ
is/VBZ
true/JJ
,/,
what/WP
is/VBZ
the/DT
point/NN
of/IN
taking/VBG
the/DT
test/NN
?/.
====================
It/PRP
is/VBZ
simply/RB
not/RB
ethical/JJ
to/TO
entice/VB
people/NN
to/TO
pay/VB
for/IN
useless/NN
products/NNS
./.
====================
One/CD
non-profit/NN
technology/NN
policy/NN
think/VBP
tank/NN
,/,
called/VBN
TechFreedom/JJ
,/,
launched/VBN
an/DT
online/JJ
petition/NN
asking/VBG
the/DT
FDA/NN
to/TO
reverse/JJ
the/DT
ban/NN
and/CC
collected/JJ
a/DT
total/JJ
of/IN
10,073/CD
signatures/NNS
on/IN
January/NN
18/CD
,/,
2014/CD
[/(
15/CD
]/)
./.
====================
Many/JJ
petitioners/NNS
said/JJ
that/DT
their/PRP$
genetic/JJ
codes/VBZ
belong/IN
to/TO
them/PRP
,/,
so/RB
they/PRP
have/VBP
the/DT
``/NN
right/JJ
to/TO
know/VB
''/NNP
what/WP
is/VBZ
written/RB
there/EX
,/,
and/CC
that/IN
the/DT
assumption/NN
that/DT
they/PRP
should/MD
be/VB
``/CD
protected/VBD
from/IN
knowing/JJ
''/NNP
because/IN
they/PRP
are/VBP
not/RB
smart/VB
enough/IN
to/TO
understand/VB
is/VBZ
simply/RB
insulting/VBG
./.
====================
All/DT
of/IN
these/DT
concerns/NNS
are/VBP
understandable/JJ
,/,
but/CC
we/PRP
insist/VBP
that/DT
genetic/JJ
testing/NN
with/IN
scientific/JJ
flaws/VBZ
itself/PRP
is/VBZ
a/DT
great/JJ
harm/VBP
to/TO
consumers/NNS
and/CC
that/IN
those/DT
flaws/VBZ
need/RB
to/TO
be/VB
addressed/VBN
before/IN
discussing/VBG
the/DT
protection/NN
of/IN
anyone/DT
's/POS
right/JJ
to/TO
know/VB
or/CC
not/RB
to/TO
know/VB
./.
====================
Of/IN
course/NN
,/,
there/EX
are/VBP
many/JJ
people/JJ
who/WP
support/VBP
the/DT
FDA/NN
's/POS
action/NN
as/IN
protection/NN
of/IN
consumers/NNS
from/IN
potentially/RB
invalid/JJ
and/CC
almost/RB
useless/RB
information/NN
./.
====================
Among/IN
the/DT
professional/JJ
proponents/NNS
,/,
Baudhuin/NN
emphatically/RB
wrote/VBP
in/IN
her/RB
opinion/NN
paper/NN
that/IN
if/IN
it/PRP
is/VBZ
too/RB
burdensome/JJ
to/TO
prove/VB
the/DT
validity/NN
of/IN
the/DT
information/NN
that/IN
the/DT
DTC/NN
testing/VBG
companies/NNS
offer/VBP
,/,
they/PRP
should/MD
not/RB
sell/JJ
the/DT
information/NN
in/IN
the/DT
first/JJ
place/NN
[/(
2/CD
]/)
./.
====================
Some/DT
consumers/NNS
are/VBP
already/RB
initiating/VBG
procedures/NNS
for/IN
class-action/NN
lawsuits/NNS
against/IN
23andMe/JJ
,/,
claiming/VBG
that/DT
it/PRP
is/VBZ
selling/JJ
misleading/VBG
information/NN
[/(
2/CD
]/)
./.
====================
On/IN
November/NN
27/CD
,/,
2013/CD
,/,
just/RB
5/CD
days/NNS
after/IN
the/DT
FDA/NN
's/POS
warning/VBG
letter/RBR
was/VBD
sent/JJ
to/TO
23andMe/JJ
,/,
the/DT
first/JJ
class-action/NN
lawsuit/NN
was/VBD
already/RB
filed/VBN
in/IN
the/DT
Southern/NN
District/NN
Court/NN
of/IN
California/NN
[/(
16/CD
]/)
./.
====================
However/RB
,/,
even/RB
among/IN
the/DT
supporters/NNS
,/,
some/DT
people/JJ
saw/NN
the/DT
FDA/NN
's/POS
action/NN
as/IN
rather/RB
unusual/JJ
,/,
because/IN
the/DT
decision/NN
was/VBD
largely/RB
based/VBN
on/IN
its/PRP$
theoretical/JJ
harm/VBP
rather/RB
than/IN
actual/JJ
harm/VBP
,/,
which/WDT
the/DT
FDA/NN
has/VBZ
usually/RB
been/VBN
waiting/VBG
for/IN
before/IN
acting/VBG
./.
====================
In/IN
Korea/NN
,/,
Lee/NNP
and/CC
Lee/NNP
[/(
4/CD
]/)
of/IN
the/DT
KHIDI/NN
submitted/VBN
a/DT
report/NN
in/IN
June/JJ
2014/CD
to/TO
the/DT
PPJRAI/NN
,/,
titled/JJ
``/CD
Market/NN
Analysis/NN
and/CC
Strategies/NNS
for/IN
Regulatory/JJ
Reform/NN
in/IN
Medical/JJ
Industry/NN
,/,
''/NNP
which/WDT
expressed/VBD
a/DT
stance/NN
somehow/RB
different/JJ
from/IN
that/DT
of/IN
the/DT
US/NN
FDA/NN
[/(
4/CD
]/)
./.
====================
In/IN
this/DT
report/NN
,/,
they/PRP
suggested/VBD
that/IN
it/PRP
will/MD
help/VB
to/TO
expand/CC
the/DT
PGS/NN
market/NN
if/IN
genetic/JJ
testing/NN
agencies/NNS
are/VBP
exempted/VBN
from/IN
providing/VBG
at/IN
least/JJS
two/CD
scientific/JJ
reports/NNS
to/TO
support/VB
or/CC
prove/JJ
the/DT
clinical/JJ
validity/NN
of/IN
their/PRP$
tests/NNS
when/WRB
they/PRP
make/VBP
a/DT
notification/NN
of/IN
their/PRP$
testing/VBG
items/VBZ
for/IN
disease/NN
prevention/NN
to/TO
the/DT
Korea/NN
Center/JJ
for/IN
Disease/NN
Control/NN
and/CC
Prevention/NN
[/(
4/CD
]/)
./.
====================
This/DT
recommendation/NN
seems/VBZ
to/TO
be/VB
in/IN
opposition/NN
to/TO
the/DT
US/NN
FDA/NN
's/POS
./.
====================
Also/RB
,/,
they/PRP
recommended/VBD
an/DT
amendment/JJ
to/TO
the/DT
Bioethics/NNS
and/CC
Safety/NN
Act/NN
,/,
which/WDT
will/MD
allow/VB
non-medical/JJ
institutions/NNS
,/,
such/JJ
as/IN
biotechnology/NN
companies/NNS
,/,
to/TO
perform/VB
health-related/JJ
PGSs/NNS
,/,
at/IN
least/JJS
for/IN
disease/NN
prediction/NN
and/CC
prevention/NN
(/(
not/RB
diagnosis/NN
)/)
[/(
4/CD
]/)
./.
====================
However/RB
,/,
they/PRP
added/VBD
that/DT
this/DT
predictive/JJ
,/,
preventive/JJ
genetic/JJ
testing/NN
should/MD
be/VB
performed/VBN
under/IN
the/DT
supervision/NN
of/IN
physicians/NNS
,/,
like/IN
the/DT
US/NN
FDA/NN
insists/NNS
./.
====================
Since/IN
these/DT
recommendations/NNS
are/VBP
supposed/VBN
be/VB
delivered/VBN
to/TO
the/DT
ministries/NNS
involved/VBN
in/IN
regulating/VBG
genetic/JJ
testing/NN
,/,
we/PRP
may/MD
guess/VB
which/WDT
direction/JJ
our/PRP$
governmental/JJ
regulation/NN
system/NN
will/MD
take/VB
in/IN
the/DT
near/JJ
future/JJ
./.
====================
23andMe/DT
is/VBZ
now/RB
working/VBG
to/TO
get/VB
FDA/NN
approval/JJ
for/IN
its/PRP$
health/NN
tests/NNS
;/:
the/DT
company/JJ
submitted/VBN
seven/CD
health-related/JJ
tests/NNS
to/TO
the/DT
FDA/NN
for/IN
review/NN
in/IN
July/RB
2014/CD
;/:
it/PRP
plans/VBZ
to/TO
submit/VB
100/CD
additional/JJ
tests/NNS
before/IN
the/DT
end/NN
of/IN
the/DT
year/NN
[/(
17/CD
]/)
./.
====================
However/RB
,/,
it/PRP
is/VBZ
very/RB
likely/JJ
that/IN
this/DT
process/NN
will/MD
take/VB
years/NNS
./.
====================
However/RB
,/,
they/PRP
have/VBP
been/VBN
trying/VBG
different/JJ
strategies/NNS
,/,
including/VBG
finding/NN
new/JJ
markets/NNS
./.
====================
From/IN
October/NN
2014/CD
,/,
23andMe/JJ
has/VBZ
begun/VBN
selling/VBG
its/PRP$
health-related/JJ
genetic/JJ
tests/NNS
in/IN
Canada/NN
,/,
despite/IN
still/RB
being/VBG
blocked/VBN
by/IN
the/DT
US/NN
FDA/NN
from/IN
offering/VBG
its/PRP$
health/NN
risk-related/JJ
service/RB
[/(
18/CD
]/)
./.
====================
Downing/VBG
and/CC
Ross/NNP
wrote/VBP
that/DT
sales/NNS
of/IN
DTC/NN
genetic/JJ
tests/NNS
,/,
including/VBG
23andMe/JJ
's/POS
PGS/NN
,/,
could/MD
be/VB
resumed/VBN
only/RB
if/IN
reliable/JJ
data/NNS
have/VBP
been/VBN
accumulated/VBN
that/DT
can/MD
demonstrate/VB
that/IN
the/DT
tests/NNS
have/VBP
positive/JJ
clinical/JJ
validity/NN
and/CC
can/MD
be/VB
used/VBN
safely/RB
without/IN
professional/JJ
supervision/NN
[/(
19/CD
]/)
./.
====================
As/IN
we/PRP
mentioned/VBD
above/JJ
,/,
this/DT
task/NN
is/VBZ
easier/RBR
said/NN
than/IN
done-it/NN
can/MD
be/VB
practically/RB
impossible/JJ
./.
====================
Even/RB
the/DT
same/JJ
authors/NNS
actually/RB
emphasized/VBN
the/DT
importance/NN
of/IN
the/DT
physician/JJ
's/POS
role/NN
in/IN
the/DT
same/JJ
article/NN
,/,
which/WDT
can/MD
``/VB
contextualize/VBP
''/CD
test/NN
results/VBZ
for/IN
maximizing/VBG
clinical/JJ
benefit/NN
,/,
preventing/VBG
adverse/JJ
effects/NNS
,/,
and/CC
genuinely/RB
empowering/VBG
patients/NNS
[/(
19/CD
]/)
./.
====================
Zettler/NN
et/FW
al/JJ
./.
====================
[/(
20/CD
]/)
wrote/VBP
that/DT
the/DT
FDA/NN
's/POS
warning/VBG
to/TO
23andMe/JJ
may/MD
effectively/RB
mark/VBP
the/DT
end/NN
of/IN
the/DT
DTC/NN
genetic/JJ
testing/NN
field/NN
,/,
at/IN
least/JJS
in/IN
the/DT
United/JJ
States/NNS
,/,
if/IN
23andMe/DT
's/POS
PGS/NN
can/MD
not/RB
meet/VB
the/DT
FDA/NN
's/POS
standards/NNS
for/IN
clinical/JJ
validity/NN
./.
====================
DTC/NN
genetic/JJ
testing/NN
companies/NNS
,/,
such/JJ
as/IN
Navigenics/NNS
and/CC
deCODEme/JJ
,/,
were/VBD
already/RB
sold/JJ
to/TO
other/JJ
firms/NNS
and/CC
stopped/VBD
their/PRP$
health-related/JJ
services/VBZ
in/IN
2012/CD
[/(
20/CD
]/)
./.
====================
The/DT
problem/NN
is/VBZ
that/DT
no/DT
one/CD
knows/VBZ
,/,
at/IN
the/DT
moment/NN
,/,
how/WRB
strict/JJ
the/DT
FDA/NN
's/POS
standards/NNS
for/IN
clinical/JJ
validity/NN
will/MD
be/VB
./.
====================
Another/DT
question/NN
will/MD
definitely/RB
be/VB
this/DT
:/:
what/WP
will/MD
happen/VB
to/TO
whole-genome/DT
and/CC
exome/JJ
sequencing/NN
,/,
which/WDT
is/VBZ
already/RB
replacing/VBG
single-gene/JJ
tests/NNS
or/CC
SNP/NN
chips/NNS
,/,
in/IN
terms/NNS
of/IN
clinical/JJ
application/NN
?/.
====================
Interestingly/RB
,/,
just/RB
3/CD
days/NNS
before/IN
warning/VBG
23andMe/JJ
,/,
the/DT
FDA/NN
authorized/VBN
Illumina/NN
to/TO
market/JJ
four/CD
``/JJ
next-generation/JJ
''/RB
gene/NN
sequencing/VBG
devices/VBZ
:/:
a/DT
sequencing/JJ
platform/VBP
,/,
two/CD
assays-the/DT
MiSeqDx/NNP
Cystic/JJ
Fibrosis/NN
139-Variant/JJ
Assay/NN
and/CC
MiSeqDx/NNP
Cystic/JJ
Fibrosis/NN
Clinical/JJ
Sequencing/NN
Assay-and/CC
a/DT
``/JJ
universal/JJ
kit/NN
''/NNP
that/IN
allows/VBZ
laboratories/NNS
that/IN
purchase/JJ
the/DT
platform/NN
to/TO
develop/VB
and/CC
validate/VBP
sequencing/VBG
of/IN
any/DT
part/NN
of/IN
a/DT
patient/NN
's/POS
genome/NN
and/CC
to/TO
find/VB
any/DT
differences/NNS
between/IN
the/DT
patient/NN
and/CC
the/DT
reference/NN
[/(
21/CD
]/)
./.
====================
What/IN
made/VBD
the/DT
difference/NN
in/IN
the/DT
fate/NN
of/IN
these/DT
two/CD
companies/NNS
?/.
====================
We/PRP
have/VBP
not/RB
made/VBN
an/DT
inquiry/JJ
about/RB
this/DT
directly/RB
to/TO
the/DT
US/NN
FDA/NN
but/CC
can/MD
get/VB
some/DT
clues/NNS
from/IN
the/DT
FDA/NN
's/POS
press/NN
release/NN
about/IN
this/DT
authorization/NN
./.
====================
First/RB
of/IN
all/DT
,/,
it/PRP
said/JJ
that/DT
these/DT
assays/NNS
will/MD
check/VB
``/CD
specific/JJ
points/NNS
in/IN
the/DT
patient/NN
's/POS
CFTR/NN
gene/NN
sequence/NN
''/CD
to/TO
detect/VB
known/VBN
and/CC
unknown/JJ
variants/NNS
./.
====================
Their/PRP$
reports/NNS
will/MD
include/VBP
the/DT
existence/NN
of/IN
genetic/JJ
variants/NNS
in/IN
the/DT
gene/NN
sequence/NN
that/WDT
are/VBP
known/VBN
to/TO
be/VB
associated/VBN
with/IN
one/CD
specific/JJ
disease/NN
but/CC
will/MD
not/RB
provide/VB
medical/JJ
interpretations/NNS
of/IN
the/DT
findings/NNS
./.
====================
Second/JJ
,/,
it/PRP
did/VBD
not/RB
mention/NN
non-patient/JJ
customers/NNS
at/IN
all/DT
./.
====================
Finally/RB
,/,
the/DT
press/NN
release/NN
also/RB
emphasized/VBN
the/DT
clinician/JJ
's/POS
involvement/NN
./.
====================
It/PRP
said/JJ
that/IN
``/RB
this/DT
information-rich/JJ
technology/NN
is/VBZ
becoming/VBG
more/RBR
accessible/JJ
for/IN
use/NN
by/IN
physicians/NNS
in/IN
the/DT
care/JJ
of/IN
their/PRP$
patients/NNS
''/RB
and/CC
that/IN
``/RB
the/DT
new/JJ
technology/NN
also/RB
gives/VBZ
physicians/NNS
the/DT
ability/NN
to/TO
take/VB
a/DT
broader/RBR
look/NN
at/IN
their/PRP$
patients/NNS
'/``
genetic/JJ
makeup/VBP
and/CC
can/MD
help/VB
in/IN
diagnosing/VBG
disease/NN
or/CC
identifying/VBG
the/DT
cause/JJ
of/IN
symptoms/NNS
''/NNP
[/(
21/CD
]/)
./.
====================
We/PRP
believe/VBP
that/IN
the/DT
US/NN
FDA/NN
's/POS
authorization/NN
of/IN
the/DT
MiSeqDX/NN
for/IN
cystic/JJ
fibrosis/NN
reflects/VBZ
the/DT
agency/NN
's/POS
attitude/VBP
towards/IN
any/DT
tests/NNS
involving/VBG
the/DT
human/JJ
genome/NN
./.
====================
Therefore/RB
,/,
from/IN
this/DT
,/,
we/PRP
can/MD
guess/VB
the/DT
answer/JJR
to/TO
the/DT
question/NN
we/PRP
posed/VBD
above/JJ
:/:
any/DT
genetic/genome/exome/JJ
tests/NNS
will/MD
be/VB
required/VBN
to/TO
prove/VB
their/PRP$
analytical/JJ
and/CC
clinical/JJ
validity/NN
and/CC
clinical/JJ
utility/NN
for/IN
specific/JJ
diseases/NNS
and/CC
conditions/NNS
if/IN
they/PRP
are/VBP
intended/VBN
for/IN
medical/JJ
applications/NNS
./.
====================
Until/IN
then/RB
,/,
we/PRP
suggest/VBP
that/IN
their/PRP$
application/NN
should/MD
be/VB
restricted/JJ
to/TO
research/NN
applications/NNS
and/CC
family/NN
studies/NNS
for/IN
diagnosing/VBG
genetic/JJ
disorders/NNS
of/IN
unknown/JJ
etiology/NN
./.
====================
When/WRB
a/DT
human/JJ
being/VBG
is/VBZ
involved/VBN
,/,
we/PRP
believe/VBP
that/IN
the/DT
most/JJS
important/JJ
ethics/NNS
principle/JJ
is/VBZ
``/CD
Do/NN
no/DT
harm/NN
./.
''/CD
====================
